Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,266.00-3.92%ETH$2,382.91-4.21%GOLD$4,044.50-0.39%OIL$99.03-0.44%
Smart Investors Daily
SID Premium
GO

NASDAQ · GOSS

Gossamer Bio, Inc.

Healthcare · Biotechnology

$9.79

Down-$0.33 (-3.37%)

Updated Oct 22, 2026, 8:56 PM

SID Score

6.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
824.25M
P/E ratio
-5.95
Dividend yield
0.00%
52-week range
$0.11 – $14.75
Volume
218.97K
Avg. volume
3.24M

Price performance · GOSS

GOSS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

GOSS closed at $9.79 after 21 trading sessions, down 10.92% for the selected period.

Last close
$9.79
Period change
-10.92%
Period low
$8.43
Period high
$11.85
Daily close
View OHLC price history
GOSS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$9.50$10.39$9.50$9.79218.97K
Oct 20, 2026$8.41$9.625$8.29$9.58214.55K
Oct 19, 2026$8.80$8.885$8.3105$8.43181.02K
Oct 16, 2026$8.88$8.995$8.5101$8.77171.14K
Oct 15, 2026$8.86$9.18$8.73$8.89197.8K
Oct 14, 2026$9.59$9.6406$8.77$8.905361.19K
Oct 13, 2026$9.83$10.0343$9.26$9.76481.77K
Oct 12, 2026$9.54$9.54$8.99$9.28155.21K
Oct 9, 2026$9.93$10.0999$9.20$9.31291K
Oct 8, 2026$10.02$10.2758$9.657$9.88197.41K
Oct 7, 2026$10.38$10.66$9.7744$10.18280.65K
Oct 6, 2026$10.77$10.93$10.50$10.78197.22K
Oct 5, 2026$10.70$10.9856$10.00$10.65391.01K
Oct 2, 2026$11.19$11.19$10.1871$10.71236.38K
Oct 1, 2026$11.63$12.14$10.80$10.93352.08K
Sep 30, 2026$11.53$12.46$11.16$11.85382.02K
Sep 29, 2026$11.68$11.845$11.21$11.58384.01K
Sep 28, 2026$10.46$11.85$10.33$11.52516.47K
Sep 25, 2026$10.93$11.01$10.2225$10.94426.59K
Sep 24, 2026$10.76$11.679$10.75$10.93236.25K
Sep 23, 2026$11.69$11.97$10.03$10.99455.82K

Latest GOSS news

The latest Smart Investors Daily articles mentioning GOSS.

Stock researchCompany · Overview

GOSS research

Overview

Company profile and research snapshot.

Company profile

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.00
Implied upside
—
Analysts
15
GOSS recent ratings
DateFirmRatingTarget
Oct 15, 2026Chardan CapitalBuy—
Oct 13, 2026Chardan CapitalBuy—
Sep 21, 2026HC Wainwright & Co.Buy—
Aug 14, 2026Piper SandlerOverweight—
Jul 28, 2026Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 17, 2026

Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks

Gossamer Bio’s updated model now points to a fair value of $95.40, up from $82.48, which marks a meaningful shift in the price target assumptions for the stock. Recent Street research links these higher targets to differing views on seralutinib, the regulatory path and how much risk investors should assign to the Phase 3 PROSERA miss and upcoming FDA review. As you read on, you will see how these changing inputs shape the evolving Gossamer Bio narrative and what to watch next. Analyst Price...

Yahoo · Oct 1, 2026

Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk and reward for seralutinib as it moves toward a planned PAH NDA submission, with analysts weighing FDA feedback, trial data and single asset concentration. As you read on, you will see how to track these changing targets and what might matter most for following the evolving...

Yahoo · Sep 23, 2026

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By